Jordi Remon· @JordiRemon · X·· 21 小时前评分45
正文 · 机器翻译
Temab-A 是一种抗 MET 的 ADC，在 MET+ 非鳞状、经治疗的 wt 和 EGFRm NSCLC 中显示出良好活性。但：日常实践中检测该生物标志物容易吗？在 EGFRm 队列中，联合 osimertinib 后活性是否更高？MET+ 是否确实是 Temab-A 在 EGFRm 中活性的预测性生物标志物？脑部活性如何？ #ESMO2026
26 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
2719RO按 Rapid oral 1: NSCLC, metastatic 对上
FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)
https://esmocongress.esmo.orgLBA73按 Rapid oral 1: NSCLC, metastatic 对上
PACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line
https://esmocongress.esmo.org来源：Jordi Remon · x.com